SEATTLE | Dec. 19, 2016

FOR IMMEDIATE RELEASE: Seattle | Dec. 19, 2016 : IDRI (Infectious Disease Research Institute) is expanding its Board of Directors, comprised of international leaders in industry and academia, with the recent addition of Norman Baylor, Ph.D., who has extensive experience in the field of vaccines and vaccine-related products, including 20 years with the Food and Drug Administration (FDA).

“Dr. Baylor’s wealth of knowledge and scientific expertise, particularly in the field of vaccines, makes him a terrific addition to IDRI’s board,” said Steven G. Reed, Ph.D., IDRI President, CEO and Founder. “With our focus on developing products to solve global health challenges caused by infectious diseases, IDRI will benefit from his global perspective and experience in developing and licensing vaccines.”

Baylor currently serves as President and CEO of Biologics Consulting, a regulatory and product baylor_norman-02_webdevelopment consulting firm for biologics, pharmaceuticals and medical devices based in Alexandria, VA. He joined Biologics Consulting after 20 years with the FDA, most recently as the director of the Office of Vaccines Research and Review. During his tenure at the FDA, Baylor evaluated and facilitated the development and licensure of numerous new vaccines, such as acellular pertussis, varicella, pneumococcal conjugate, human papillomavirus (HPV) influenza, zoster and all of the new-generation combination vaccines.

Baylor served as the FDA’s liaison to the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, the US Department of Health and Human Services National Vaccine Advisory Committee, and the Advisory Commission on Childhood Vaccines. Baylor continues to serve as an expert advisor to the World Health Organization on several global vaccine initiatives.

“I am honored to be joining IDRI’s Board of Directors,” said Baylor. “IDRI’s focus on research and development of products that  address global public health needs is consistent with my career goal of facilitating the development, licensure and availability of products that will have a positive impact on the health of the global community.  I look forward to working with the Board to foster the mission of IDRI.”

Baylor holds a Ph.D. in molecular microbiology from the University of Kentucky. He earned a bachelor’s degree in medical microbiology from the University of Wisconsin-Madison and a master’s degree in microbial genetics from the University of Kentucky.

About IDRI

As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. IDRI combines passion for improving human health with the understanding that it is not just what our scientists know about disease, but what we do to change its course that will have the greatest impact. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit


IDRI: Lee Schoentrup | 206.858.6064 |